Fate therapeutics inc (FATE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-33,520

-28,302

-26,609

-23,478

-19,760

-16,027

-16,782

-19,654

-14,135

-12,497

-10,684

-9,645

-10,126

-7,940

-8,737

-8,408

-8,377

-7,446

-6,886

-7,779

-7,881

-6,233

-6,603

-6,067

-6,980

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

705

623

587

543

440

327

310

281

286

290

244

231

206

203

218

233

227

210

187

162

128

125

115

133

123

Stock-based compensation

6,913

4,583

4,573

4,386

3,868

1,784

1,642

1,485

1,382

895

871

973

867

819

782

786

797

480

574

738

608

612

527

424

871

Amortization of debt discounts and debt issuance costs

-

68

15

17

15

19

19

19

19

19

19

19

24

28

33

38

40

44

45

43

44

7

3

6

8

Accretion and amortization of premiums and discounts on investments, net

-271

-80

255

298

5

36

87

137

75

4

7

13

1

-13

-41

-62

-55

-

-

-

-

-

-

-

-

Amortization of collaboration contract asset

168

187

162

164

107

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash interest expense

-

-

79

80

79

94

94

93

92

94

89

61

77

96

112

127

157

157

165

165

164

91

59

7

10

Deferred rent

-

-

-

-

-

-55

-66

-2

-69

-269

-268

-276

-272

-1

-2

3

7

8

6

0

10

17

17

9

9

Deferred revenue

-515

-1,301

-2,430

-2,663

-2,132

3,838

9,474

-527

-526

-526

-526

-1,579

526

-4,276

526

527

822

-

-

-

-

-

-

-

-

Stock-based milestone charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

375

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-636

2,778

-348

273

-792

1,452

222

500

-164

815

-23

-289

-75

462

-383

190

112

395

87

-72

-303

666

-164

-52

-304

Accounts payable and accrued expenses

-3,316

1,511

3,659

365

-1,258

336

1,175

2,070

673

1,554

-184

-536

1,677

217

176

378

790

-282

-97

587

269

-73

228

-35

43

Right-of-use assets and lease liabilities, net

1,985

32

33

348

361

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-26,673

-25,535

-19,838

-20,309

-17,493

-11,020

-3,556

-11,523

-12,551

-10,721

-9,769

-8,872

-7,455

-7,551

-7,516

-7,504

-7,252

-6,970

-7,131

2,079

-6,375

-6,154

-5,521

-5,489

-5,255

Investing activities
Purchases of property and equipment

1,070

2,590

1,264

1,795

1,746

1,117

724

278

184

797

362

411

155

40

33

206

178

178

655

213

452

271

187

26

398

Purchases of investments

-

-

-

-

-

0

0

0

55,660

0

0

0

39,971

0

3,509

0

16,166

-

-

-

-

-

-

-

-

Maturities of investments

24,844

34,750

37,550

16,000

10,500

17,500

14,000

14,000

12,000

14,000

14,000

1,750

1,750

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

23,774

-110,516

36,286

-91,977

8,754

16,383

13,276

13,722

-43,844

13,203

13,638

1,339

-38,376

5,978

458

5,794

-16,344

-178

-655

-213

-452

-271

-187

-26

-398

Financing activities
Issuance of common stock from equity incentive plans, net of issuance costs

1,011

413

163

688

1,258

779

1,133

175

606

33

106

32

34

19

24

-4

147

35

221

89

75

-

-

-

-

Proceeds from public offering of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

Issuance costs from public offering of common stock

-

-

-

-

-

-

-

19

251

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from CIRM award

440

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal repayments of long–term debt

-

-

-

-

-

-

-

-

-

0

6,709

2,044

2,011

1,975

1,938

1,903

1,873

-

-

-

-

0

750

500

500

Net cash provided by financing activities

1,451

-13,723

161,705

688

1,258

1,904

137,365

1,156

355

43,239

8,299

-2,012

-2,170

53,083

8,287

-1,907

-1,726

-900

-533

36,961

75

9,996

9,226

-354

-502

Net change in cash, cash equivalents and restricted cash

-1,448

-149,774

178,153

-111,598

-7,481

7,267

147,085

3,355

-56,040

45,721

12,168

-9,545

-48,001

51,510

1,229

-3,617

-25,322

-8,048

-8,319

38,827

-6,752

3,571

3,518

-5,869

-6,155

Supplemental disclosure of cash flow information
Interest paid

-

1,353

312

317

309

313

316

314

299

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental schedule of noncash investing and financing activities
Purchases of property and equipment in accounts payable

343

-202

-249

-429

1,482

-13

-423

216

257

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of use assets obtained in exchange for lease obligations

47,808

-

-

-

7,705

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-